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to its poor in vitro activity against M. kansasii. Improved thera-
peutic regimens for this pathogen would be useful. The purpose of
the present study was to evaluate the comparative in vitro activi-
ties of TR-1710, a new pyrimidoindole DNA gyraseB inhibitor, and
moxiﬂoxacin, a GyrA inhibitor, against twenty two isolates of M.
kansasii. It is unlikely that cross resistance will be a problem with
gyrase inhibitors targeting different enzyme subunits.
Methods&Materials:TR-1710andmoxiﬂoxacinwereobtained
from Cubist Pharmaceuticals (San Diego, CA) and Bayer Pharma-
ceuticals (West Haven, CT) respectively. These compounds were
dissolved in DMSO to a concentration of 1mg/ml prior to freez-
ing at -200C. They were tested in Middlebrook 7H9 broth, pH6.6
supplemented with 10% Middlebrook albumin-dextrose-catalase
enrichmentat2g/ml–0.002g/ml inpolystyrene96-well round-
bottom microtiter plates. To each well, 50l of mycobacterial cell
suspension was added to yield an initial concentration of about 1
x 105 CFU/ml (range for various isolates tested was 3.8 x103 – 1.2
x 106CFU/ml). Plates were incubated at 370C in ambient air for 7 -
10 days prior to reading.
Results:TR-1710andmoxiﬂoxacinhad similar activities against
M. kansasii in vitro. The MIC50/MIC90 (g/ml) of TR-1710 and
moxiﬂoxacin were 0.03/0.06 and 0.06/0.50 respectively.
Conclusion: Based on TR-1710’s promising in vitro activity, it
would be interesting to evaluate the comparative activities of TR-
1710 and moxiﬂoxacin in a murine model of M. kansasii infection,
as the next step in deﬁning the potential of gyrase inhibitors in the
treatment of these infections in humans.
http://dx.doi.org/10.1016/j.ijid.2014.03.838
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Background:Vancomycin iswidely used for treatment ofMRSA
infection. For safe use of vancomycin, it is important to employ
the therapeutic drug monitoring, although renal function can get
worse even by maintaining the safe concentration of vancomycin.
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) are antihypertensives which are known
to block renin-angiotensin-aldosteron system and to have renal
protecting effect. However, there has been no study investigating
the effect of ACEIs or ARBs on renal protection during vancomycin
administration. In this studywe investigated the inﬂuence of ACEIs
or ARBs on renal function during the vancomycin administration.
Methods & Materials: All the hospitalized patients who receive
vancomycin intravenously in the department of internal medicine
in the Teikyo University hospital from September 2010 to February
2013 were enrolled. Patients who received other potential nephro-
toxic agents, those who stopped receiving vancomycin due to
other reason than renal dysfunction, or those who died during the
treatment were excluded. All the patients were divided into three
groups; ACEI/ARB groups, other antihypertensive group, and non-
antihypertensive group. Clinical backgrounds, trough vancomycin
concentrations, and changes of estimated glomerular ﬁltration
rates (eGFRs) were compared by reviewing medical records. Acute
kidney injury (AKI) was deﬁned as increase in the serum creatinine
concentration of ≥0.3mg/dL from baseline.
Results: Thirty one patients were enrolled in this study.
ACEI/ARB group were nine, other antihypertensive group were
nine, and non-antihypertensive groups were 13. Among clinical
backgrounds, only the ratio of hypertension was lower in the non-
hypertensive group than in the other two groups. Mean trough
vancomycin concentrations were not different between the three
groups (15.3 vs 16.0 vs 14.7g/mL, P=0.86).Mean eGFRs at the van-
comycin initiation and at the vancomycin termination were not
statistically different between the three groups (59.0 vs 57.4 vs
58.8mL/min/1.73m2, P=0.61; 60.5 vs 57.1 vs 57.2mL/min/1.73m2,
P=0.80, respectively). The ratio of AKI was not statistically different
between the three groups (3/9 vs 1/9 vs 1/13, P=0.24).
Conclusion:ACEIs or ARBs did not protect renal function during
vancomycin administration.
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Background: Nitroxoline, a hydroxychinolin derivate, is used
for many years for treatment of urinary tract infections (UTI). Four
controlled clinical studies concerning treatment of uncomplicated
UTI (uUTI) not published yet were meta-analysed.
Methods & Materials: The individual patient data (IPD) of 466
females with acute sporadic or acute episodes of recurrent uUTI
of four prospective, controlled, single blind, randomized clinical
studieswith similar protocols using nitroxoline (250mg tid) versus
cotrimoxazole (960mg bid) or norﬂoxacin (400mg bid) as controls
for ﬁve (three studies) or ten (one study) days were meta-analysed
by the same criteria. The primary efﬁcacy was the eradication
of bacteriuria. Success was deﬁned if pretreatment bacteriuria of
≥105CFU/ml was reduced to < 104CFU/ml 7-13 days after end of
therapy (test of cure). Clinical efﬁcacy was determined by elimi-
nation of symptoms and safety by adverse events and laboratory
tests.
Results: A total of 234 patients were treated orally with nitrox-
oline and 232 with the controls. The safety of nitroxoline was very
good and comparable to the controls (total adverse events 9.4% vs
7.8%). In the modiﬁed microbiological ITT set (at least one outcome
result available), in the PP set (test of cure outcome available) and
in the modiﬁed PP set (missing test of cure rated failure) more than
90% of the patients showed eradication of bacteriuria with nitrox-
oline, which also met statistical non-inferiority compared to the
controls (10% non-inferiority margin) in all three evaluation sets.
